Senior Medical Advisor at the Cannabinoid Research Institute
Pro to the question "Should Marijuana Be a Medical Option?"
"Cannabis smoking, even of a crude, low-grade product, provides effective symptomatic relief of pain, muscle spasms, and intraocular pressure elevations in selected patients failing other modes of treatment...
It is the authors' opinion that the Compassionate IND program should be reopened and extended to other patients in need of clinical cannabis. Failing that, local, state and federal laws might be amended to provide regulated and monitored clinical cannabis to suitable candidates."
Ethan Russo, et al., "Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis," Journal of Cannabis Therapeutics, Jan. 2002
Key Experts Physicians [Physicians are the "key experts" in the medical marijuana debate because the issue is thought by many to be ultimately based on the medical value and risks of marijuana, and Physicians, with their training and clinical work, should (at least in theory) have the best knowledge of marijuana's medical value and risks.] [Note: Key Experts definition varies by sites that have this designation.]
Involvement and Affiliations:
Visiting Professor, Chinese Academy of Sciences Institute of Botany
Senior Medical Adviser, Cannabinoid Research Institute, G.W. Pharmaceuticals
Adjunct Associate Professor, Department of Pharmaceutical Sciences, University of Montana
Clinical Associate Professor, Department of Medicine, University of Washington
Conducted Missoula Chronic Cannabis Use Research Study
Member, International Cannabis Research Society
Governing Board, International Association of Cannabis as Medicine (IACM)
Adviser, Patients Out of Time
Founder, Journal of Cannabis Therapeutics
MD, University of Massachusetts School of Medicine, 1978
Residency, Neurology, University of Washington Medical Center
Residency, Pediatrics, St. Joseph Hospital Medical Center